NEW YORK CITY, NY / ACCESS Newswire / February 21, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ:BBNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Beta Bionics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On January 8, 2026, Beta Bionics reported preliminary financial results for the fourth quarter of 2026. Among other items, Beta Bionics revealed a 36% year-over-year increase in new patient starts, compared to a 68% year-over-year increase in the prior quarter.
On this news, Beta Bionics’ stock price fell $11.85 per share, or 37.03%, to close at $20.15 per share on January 9, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP
View the original press release on ACCESS Newswire
COMTEX_473973997/2457/2026-02-21T10:02:33